Novartis reported a +7% increase in Q3 net sales, reaching $13.9 billion, with core operating income growing +7%. Key growth drivers included Kisqali (+68% cc), Kesimpta (+44% cc), Pluvicto (+45% cc), and Scemblix (+95% cc). Nine-month performance saw net sales up +11% and core operating income up +18%. Full-year 2025 guidance reaffirmed.

CEO Vas Narasimhan highlighted Novartis’ strong Q3 financial performance, with key growth drivers performing well. FDA approval for Rhapsido in CSU and positive Phase III readouts for ianalumab in Sjogren’s disease were achieved. Novartis remains on track to meet its 2025 guidance and long-term growth goals.

In Q3 2025, Novartis saw net sales of $13.9 billion (+8%, +7% cc) and operating income of $4.5 billion (+24%, +27% cc). Net income was $3.9 billion (+23%, +25% cc) and EPS reached $2.04 (+29%, +31% cc). Core operating income was $5.5 billion (+6%, +7% cc), with core EPS at $2.25 (+9%, +10% cc).

Top growth drivers in Q3 included Kisqali, Kesimpta, Pluvicto, and Scemblix, contributing significantly to financial performance. These brands showed strong sales growth across regions, driving positive results for Novartis in the quarter.

Novartis continues to focus on delivering high-value medicines, operational excellence, and building trust with society. The company repurchased 66.4 million shares for $7.5 billion in the first nine months of 2025. Net debt increased to $20.4 billion by September 30, 2025, compared to $16.1 billion at the end of 2024.

Looking ahead to 2025, Novartis expects high single-digit growth in net sales and low-teens growth in core operating income, barring unforeseen events. The company remains committed to its strategic priorities, including accelerating growth, delivering returns, and strengthening its foundations for long-term success.

Read more at GlobeNewswire: Novartis delivers solid sales and core operating income